This case study highlights how SQA Solution enabled a leading pharmaceutical manufacturer to meet aggressive timelines and strict compliance requirements by deploying AI-driven validation models. Through the integration of tools like ChatGPT and Gemini, SQA Solution accelerated Maximo implementation, ensured data integrity, and delivered a defect-free go-live in a highly regulated GxP environment.
Solution: AI-Driven Validation and Predictive Compliance
SQA Solution introduced a CSA-aligned, AI-enhanced validation model using on-premise deployments of ChatGPT (OpenAI GPT-4) and Google Gemini. This architecture ensured control, data privacy, and GxP auditability. By leveraging AI in test design, data integrity assurance, and documentation automation, the company accelerated validation and mitigated compliance risk.
AI Integration across CSV & CSA Activities
- Predictive Analytics (Gemini):
- Analyzed legacy system logs and previous validation deviations
- Predicted high-risk configuration scenarios in Maximo
- Informed test prioritization under CSA principles
- Analyzed legacy system logs and previous validation deviations
- Test Case Generation (ChatGPT):
- Generated IQ, OQ, PQ test scripts based on URS, SOPs, and Maximo configuration
- Reduced writing time and ensured alignment with validation templates
- Generated IQ, OQ, PQ test scripts based on URS, SOPs, and Maximo configuration
- Real-Time Anomaly Detection:
- Flagged OQ issues such as permission mismatches, missing eSignatures, and audit trail failures
- Data Integrity Validation:
- Gemini validated 2M+ legacy records for accuracy, completeness, and Part 11 compliance
- Detected 92% of field-level anomalies before final ETL
- Gemini validated 2M+ legacy records for accuracy, completeness, and Part 11 compliance
- Documentation Automation:
- AI generated traceability matrices, deviation logs, validation summary reports
- Ensured full GAMP 5 and SOP alignment
- AI generated traceability matrices, deviation logs, validation summary reports
Implementation Timeline
- Weeks 1–4: CSA planning, AI deployment, SOP ingestion, risk assessment
- Weeks 5–8: URS finalization, data profiling, and dry-run migration with predictive QA checks
- Weeks 9–12: AI-driven test case generation and approval workflows
- Weeks 13–16: IQ/OQ/PQ execution with AI-assisted scripts and real-time Gemini alerts
- Weeks 17–20: Final documentation, stakeholder signoffs, and validation summary reports
- Week 21: Go-live with zero critical validation issues
Results & Measurable Impact
- 30% CSV timeline reduction (from 10 to 7 weeks)
- 40% reduction in manual test case authoring
- 100% data integrity across migrated records
- 0 critical post-deployment incidents or audit findings
- Fully traceable validation package aligned with regulatory expectations
Regulatory Alignment & Governance
The AI-assisted validation strategy aligned with:
- FDA 21 CFR Part 11 (Electronic Records; Electronic Signatures)
- EU GMP Annex 11 (Computerised Systems)
- ISPE GAMP 5 (Risk-Based Approach)
- ISPE GAMP Good Practice Guides (Data Integrity by Design, Testing)
- FDA Draft CSA Guidance (2022)
All AI outputs were reviewed by SMEs, version-controlled, and governed via documented change control. AI tools were validated as configurable utilities, and all artifacts were fully audit-trail enabled.
Client Testimonial
We validated the AI just like any other critical system. What surprised us was how seamlessly it plugged into our CSA framework. We hit our timeline, reduced workload, and ended up with one of the cleanest go-lives I’ve seen in 20 years.
– Director of QA Validation, Top 10 Pharma Manufacturer